BRPI1015338A2 - formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento - Google Patents

formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento

Info

Publication number
BRPI1015338A2
BRPI1015338A2 BRPI1015338A BRPI1015338A BRPI1015338A2 BR PI1015338 A2 BRPI1015338 A2 BR PI1015338A2 BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 A BRPI1015338 A BR PI1015338A BR PI1015338 A2 BRPI1015338 A2 BR PI1015338A2
Authority
BR
Brazil
Prior art keywords
salt
compound
drip
aggregate
disease
Prior art date
Application number
BRPI1015338A
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Svend Treppendahl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015338(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI1015338A2 publication Critical patent/BRPI1015338A2/pt
Publication of BRPI1015338B1 publication Critical patent/BRPI1015338B1/pt
Publication of BRPI1015338B8 publication Critical patent/BRPI1015338B8/pt
Publication of BRPI1015338C1 publication Critical patent/BRPI1015338C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
BRPI1015338A 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento BRPI1015338C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900531 2009-04-24
DKPA200900531 2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en) 2009-04-24 2010-04-16 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (4)

Publication Number Publication Date
BRPI1015338A2 true BRPI1015338A2 (pt) 2016-05-31
BRPI1015338B1 BRPI1015338B1 (pt) 2021-01-05
BRPI1015338B8 BRPI1015338B8 (pt) 2021-05-25
BRPI1015338C1 BRPI1015338C1 (pt) 2021-08-10

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015338A BRPI1015338C1 (pt) 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Country Status (35)

Country Link
US (4) US8940746B2 (pt)
EP (1) EP2421534B1 (pt)
JP (1) JP5722879B2 (pt)
KR (1) KR101779214B1 (pt)
CN (2) CN104693145A (pt)
AR (2) AR076400A1 (pt)
AU (1) AU2010238946B2 (pt)
BR (1) BRPI1015338C1 (pt)
CA (1) CA2759456C (pt)
CL (1) CL2011002631A1 (pt)
CO (1) CO6450649A2 (pt)
CR (1) CR20110554A (pt)
DK (1) DK2421534T3 (pt)
DO (2) DOP2011000319A (pt)
EA (1) EA021122B1 (pt)
ES (1) ES2512719T3 (pt)
GE (1) GEP20135938B (pt)
HK (1) HK1206732A1 (pt)
HR (1) HRP20140880T1 (pt)
IL (1) IL215362A0 (pt)
MA (1) MA33298B1 (pt)
MX (1) MX2011011119A (pt)
MY (1) MY155288A (pt)
NZ (1) NZ596431A (pt)
PL (1) PL2421534T3 (pt)
PT (1) PT2421534E (pt)
RS (1) RS53539B1 (pt)
SG (1) SG175124A1 (pt)
SI (1) SI2421534T1 (pt)
SM (1) SMT201400159B (pt)
TN (1) TN2011000504A1 (pt)
TW (1) TWI461224B (pt)
UA (1) UA106985C2 (pt)
WO (1) WO2010121621A1 (pt)
ZA (1) ZA201107731B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
CA2916175A1 (en) 2013-07-01 2015-01-08 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2017137048A1 (en) 2016-02-08 2017-08-17 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EP3478289A1 (en) 2016-07-01 2019-05-08 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
EP4681702A1 (en) * 2024-07-16 2026-01-21 PharmaPath S.A. Oral solution comprising vortioxetine hydrobromide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤

Also Published As

Publication number Publication date
PL2421534T3 (pl) 2014-12-31
MY155288A (en) 2015-09-30
US20190167667A1 (en) 2019-06-06
SI2421534T1 (sl) 2014-11-28
US10034876B2 (en) 2018-07-31
BRPI1015338C1 (pt) 2021-08-10
MX2011011119A (es) 2011-11-04
NZ596431A (en) 2012-12-21
SG175124A1 (en) 2011-12-29
TW201041604A (en) 2010-12-01
US20170224677A1 (en) 2017-08-10
US10857149B2 (en) 2020-12-08
US20120035188A1 (en) 2012-02-09
AU2010238946A1 (en) 2011-12-08
JP5722879B2 (ja) 2015-05-27
EP2421534A1 (en) 2012-02-29
US9475748B2 (en) 2016-10-25
BRPI1015338B8 (pt) 2021-05-25
RS53539B1 (sr) 2015-02-27
CN102405048A (zh) 2012-04-04
CO6450649A2 (es) 2012-05-31
US20150094316A1 (en) 2015-04-02
HK1206732A1 (en) 2016-01-15
AR122051A2 (es) 2022-08-10
TN2011000504A1 (en) 2013-05-24
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
CL2011002631A1 (es) 2012-04-09
ES2512719T3 (es) 2014-10-24
HRP20140880T1 (hr) 2014-11-07
TWI461224B (zh) 2014-11-21
WO2010121621A1 (en) 2010-10-28
EA021122B1 (ru) 2015-04-30
UA106985C2 (uk) 2014-11-10
GEP20135938B (en) 2013-10-10
DK2421534T3 (da) 2014-10-13
IL215362A0 (en) 2011-12-29
JP2012524735A (ja) 2012-10-18
DOP2011000319A (es) 2012-02-29
CA2759456C (en) 2017-10-31
KR20120022809A (ko) 2012-03-12
EA201171287A1 (ru) 2012-04-30
PT2421534E (pt) 2014-10-29
US8940746B2 (en) 2015-01-27
AU2010238946B2 (en) 2013-03-28
SMT201400159B (it) 2015-01-15
BRPI1015338B1 (pt) 2021-01-05
KR101779214B1 (ko) 2017-09-18
DOP2012000211A (es) 2013-03-31
ZA201107731B (en) 2013-02-27
MA33298B1 (fr) 2012-05-02
CN104693145A (zh) 2015-06-10
CA2759456A1 (en) 2010-10-28
AR076400A1 (es) 2011-06-08

Similar Documents

Publication Publication Date Title
BRPI1015338A2 (pt) formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112012005853A2 (pt) aplicador automático para preparações farmacêuticas líquidas, particularmente para insulina
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0908972A2 (pt) Cartucho para preparação de um líquido compreendendo uma parede de distribuição perfurável
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112014010183A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
BRPI1012276A2 (pt) "dispositivo para distribuir medicamento líquido."
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112014016287A2 (pt) composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
BRPI0912348A2 (pt) composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
HUE046557T2 (hu) Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
IL258357A (en) A semi-solid aqueous pharmaceutical preparation containing tapentadol
BR112014006420A2 (pt) compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
BR112013013522A2 (pt) polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BRPI1010300A2 (pt) processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica.
BRPI1007624A2 (pt) composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
BR112014008241A2 (pt) composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO A QUALIFICACAO DO TITULAR.